SHE: 000538

Yunnan Baiyao Group Secures Global Rights to Kyinno Biotechnology’s Antibody Drug KA-1641

July 1, 2024

•

Fineline Cube

Yunnan Baiyao Group Co., Ltd (SHE: 000538), a traditional Chinese medicine (TCM) company based in Kunming, has entered into a licensing agreement with Chinese firm Kyinno Biotechnology. Through this agreement, Yunnan Baiyao secures the global research and development (R&D), manufacturing, and commercialization rights for Kyinno’s antibody drug, KA-1641. The agreement…
Yunnan Baiyao’s Radiopharmaceutical INR101 Advances to Clinical Trial Stage with NMPA Approval

May 11, 2024

•

Fineline Cube

Yunnan Baiyao Group Co., Ltd (SHE: 000538), a traditional Chinese medicine (TCM) company based in Kunming, has received approval from the National Medical Products Administration (NMPA) in China to conduct a clinical study for its Category 1 chemical drug, INR101. The study will initially assess the drug in healthy volunteers…

Fineline Info & Tech